This paper examines the relationship between human genetics and drug metabolism, with a focus on the role of N-acetyltransferase (NAT) enzymes in the biotransformation of xenobiotics such as antibiotics. It describes the phases of hepatic drug metabolism, the cytochrome P450 enzyme system, and the distinct functions of the NAT1 and NAT2 genes. The paper explains how polymorphisms in these genes produce slow or fast acetylators, leading to adverse drug reactions or therapeutic failure — particularly in anti-tuberculosis drugs like isoniazid. Methods for detecting DNA polymorphisms, including gel electrophoresis and PCR, are reviewed. The paper concludes by evaluating both the promise of pharmacogenomics for personalized medicine and the ethical concerns surrounding genetic information access.
The paper effectively uses a causal chain structure: it traces the molecular pathway from drug ingestion through hepatic metabolism, enzymatic processing, and genetic variation, then connects each link in that chain to observable clinical outcomes (drug toxicity or therapeutic failure). This technique allows the writer to justify why genetics matters to pharmacology rather than simply asserting it.
The paper opens with an overview of drug metabolism and the role of the liver, then transitions to the cytochrome P450 system and the specific function of NAT enzymes. Two central sections address how NAT gene polymorphisms create slow and fast acetylators and what clinical consequences follow. A methods section covers detection techniques (gel electrophoresis and PCR). The final section broadens the scope to pharmacogenomics policy, weighing benefits against ethical concerns about genetic data access.
Drug metabolism in humans is an essential topic for anyone entering the pharmaceutical industry. When an individual ingests antibiotics, the body is already prepared with the proper enzymes and molecular processes that allow for the breakdown and uptake of these drugs. Xenobiotics encompass any substance foreign to the body; antibiotics fall into this category (Katzung, Masters, & Trevor, 2012). These are entities that the body does not produce naturally. Antibiotics are used for a variety of conditions, especially those involving bacterial infection in the human body. Such bacteria can cause adverse reactions that result in illness, creating the need for antibiotic treatment. Once a drug is ingested, however, it is drug metabolism that takes over.
Drug metabolism requires the liver to function properly in order to activate or deactivate certain components of an antibiotic. A large portion of all xenobiotics must pass through the liver for the drug to have any effect on the body. This is known as first-pass metabolism (Katzung, Masters, & Trevor, 2012). This same concept can also occur in the gastrointestinal tract. Once a drug is administered — most commonly orally — it is transported from the intestines to the liver through the hepatic portal circulation, where it is directly metabolized (Katzung, Masters, & Trevor, 2012). The metabolized portion of the drug then enters systemic circulation and eventually reaches the target organ.
This phase one metabolism is also known as oxidation/reduction. It is through phase two metabolism that conjugation occurs, encompassing the full breakdown of the xenobiotic. During this process, the ingested drug has either a hydroxyl or an amine group added to it in order to become activated. The enzymes that become active at this stage are the cytochrome P450 enzymes. The "450" refers to the 450 nm peak in absorption observed when heme proteins bind with carbon monoxide (Katzung, Masters, & Trevor, 2012). This enzyme system is responsible for approximately 75% of all drug metabolism. Any malfunction within this system can cause severe disruption to the body's processing of xenobiotics. The purpose of the system is to facilitate the transfer of the drug into cells — typically through the addition of R-groups to proteins — so that the drug more easily reaches its intended destination.
N-acetyltransferase (NAT) is an enzyme encoded by the NAT gene that adds an acetyl group to a drug in order to allow it to function (Meisel, 2002). NATs in humans are essential for the correct metabolism and functioning of a drug. In order for a xenobiotic to become inactive, an acetyl group must be added (Meisel, 2002). This inactivation is accomplished through an acetylation conjugation reaction, which occurs separately from phase one. Compounds are added to the remnants of the drug that make it more polar and therefore better able to pass through to target tissues. By catalyzing the conjugation process, drugs can also be excreted more quickly and efficiently. N-acetyltransferase can be divided into two distinct enzymes: NAT1 and NAT2.
NAT1 and NAT2 vary across individuals. Some individuals may have a faster or slower form of NAT1 or NAT2 than others (Boukouvala & Giannoulis, 2005). This has significant implications for drugs that require these enzymes for metabolism and excretion. As noted above, the primary function of N-acetyltransferase is to add an acetyl group that enhances a drug's solubility, which is important for clearing the drug so that it no longer affects the body (Meisel, 2002). Both NAT1 and NAT2 genes are adjacent to one another, and their effects are strongly influenced by genetic processes. Any deviation from the normal process can cause harm when a drug is ingested. Polymorphisms found on these genes have introduced an additional consideration for the pharmaceutical field when developing and testing drugs (Boukouvala & Giannoulis, 2005). Any unknown genetic variation may in fact induce a more severe situation if that mutation goes undetected.
You’re 36% through this paper. Sign up to read the remaining 3 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.